ModifiedUnitedHealthcarePolicy CS046NE.S

Gastrointestinal Disorders Diagnostic Procedures (for Nebraska Only)

This UnitedHealthcare medical policy governs coverage and medical necessity determinations for selected diagnostic procedures used in evaluation of gastrointestinal disorders for members in Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Disorders Diagnostic Procedures (for Nebraska Only)

Policy CodePolicy CS046NE.S

Change TypeTitle changerevisions to unproven procedure list and applicable codes

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionVerify member plan and obtain prior authorization when required before ordering advanced GI diagnostic procedures.

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Gastrointestinal Motility Disorders, Diagnosis and Treatment (for Nebraska Only)' and coverage rationale language pertaining to gastric electrical stimulation (GES) therapy was removed and relocated to a different medical policy.

Specific device examples removed from list of unproven/not medically necessary procedures.

Removed CPT codes 43647, 43648, 43881, 43882, 64590, and 64595 from Applicable Codes.

Added definitions for Achalasia and Functional Lumen Imaging Probe (FLIP).

6CPT codes removed from Applicable Codes

1New procedure added to unproven list

NebraskaState-specific application

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

MultipleEvidence sources cited

Coverage Criteria and Unproven Procedures

Procedures considered unproven / not medically necessary

The following procedures are considered unproven and not medically necessary due to insufficient evidence of efficacy:

Unproven procedures: Magnetic Resonance Imaging (MRI) Defecography for evaluating constipation and anorectal or pelvic floor disorders; Cutaneous, mucous, or serosal Electrogastrography, electroenterography, or Body Surface Gastric Mapping for diagnosing intestinal or gastric disorders including gastroparesis; Esophageal Mucosal Integrity Testing by electrical impedance for diagnosis or monitoring of GERD, eosinophilic esophagitis (EoE), or nonacid reflux disease; Functional Lumen Imaging Probe (FLIP) technology for diagnosing achalasia.

Listed explicitly as unproven/not medically necessary in policy.

Functional Lumen Imaging Probe (FLIP) — complementary use

FLIP/EndoFLIP is described as a complementary tool and may be useful in limited circumstances:

FLIP appropriate uses: FLIP may be useful for patients who cannot tolerate or complete standard manometry and to assess esophagogastric junction opening dynamics and esophageal wall stiffness during endoscopy; clinicians should not make diagnosis or treatment decisions based on FLIP alone.

Role is evolving; further studies and standardized protocols are needed.

MRI Defecography — adjunctive/triage role

MRI defecography (MRD) has mixed evidence and is generally considered adjunctive or a triage test rather than a replacement for evacuation proctography (fluoroscopic defecography):

When MRD may be used: MRD may be used when anorectal manometry (ARM) and balloon expulsion test (BET) are inconclusive or when additional anatomic detail is needed for preoperative planning; in selected cases MRD can confirm or exclude defecatory disorders.

Supported by AGA/ACG/ASCRS guidance as an adjunct when basic testing is inconclusive.

Limitations of MRD: Existing evidence indicates MRD is not consistently superior to fluoroscopic defecography, has lower technical success in some series, may under-detect enteroceles, intussusception and rectocele versus video/fluoroscopic defecography, and heterogenous protocols affect sensitivity; MRD is therefore considered a triage/adjunct test rather than a replacement for evacuation proctography.

Cochrane and comparative studies report MRD does not meet criteria to replace evacuation proctography as reference standard.

EGG/BSGM — investigational/phenotyping

EGG and BSGM (including Gastric Alimetry) are investigational/adjunctive with evolving evidence for diagnostic accuracy and clinical utility:

Current evidence on EGG/BSGM: Systematic reviews and comparative studies report differences in spectral metrics between patients and controls and improved phenotyping and patient-level classification with BSGM versus traditional EGG; however, there is insufficient evidence that use of EGG or BSGM improves patient-important outcomes or should replace established reference tests such as gastric emptying scintigraphy. Additional validation, standardized protocols, and clinical utility studies are needed.

ECRI and systematic reviews judged available evidence low quality and called for further studies.

Evidence synthesis and guideline context

Summary of evidence and guideline positions informing coverage considerations

EGG/BSGM evidence summary: BSGM demonstrates improved frequency stability, stronger symptom correlations, and higher patient-level classification accuracy than traditional EGG in comparative studies, but studies are limited by heterogeneous methodologies, small sample sizes, and lack of demonstrated impact on patient-important outcomes.

Reported in Schamberg et al. 2023, Gharibans et al. 2022, and systematic reviews.

MI testing evidence summary: Balloon mucosal impedance testing and other mucosal integrity measurements show distinct impedance patterns that may differentiate GERD and EoE in small studies, but the evidence is limited and clinical utility for improving outcomes has not been established; reviews (Hayes, ECRI) call for more validation and larger clinical utility studies.

Hayes and ECRI evidence assessments highlight limited data and evolving technology.

Guideline positions: Major gastroenterology societies have not endorsed routine use of EGG or mucosal integrity testing; AGA and ACG guidance note FLIP is complementary and should not be used alone for diagnosis or routine assessment, and do not recommend EGG or MI testing as standard diagnostic tools due to insufficient development and evidence.

The policy identifies the following procedures as unproven and not medically necessary due to insufficient evidence of efficacy: Magnetic Resonance Imaging (MRI) Defecography for evaluation of constipation and anorectal/pelvic floor disorders; cutaneous, mucous, or serosal electrogastrography, electroenterography, or body surface gastric mapping for diagnosing intestinal or gastric disorders (including gastroparesis); esophageal mucosal integrity testing by electrical impedance for diagnosis or monitoring of GERD, eosinophilic esophagitis (EoE), and nonacid reflux disease; and Functional Lumen Imaging Probe (FLIP) technology for diagnosing achalasia.

Functional Lumen Imaging Probe (FLIP/EndoFLIP) is described as an FDA‑available, complementary tool that may be useful in selected circumstances (for example when standard manometry cannot be completed) to assess esophagogastric junction opening dynamics and esophageal wall stiffness; however, the AGA and this policy state that clinicians should not make a diagnosis or treatment decision based on FLIP assessment alone and FLIP should not be used as the sole basis for routine diagnostic decision‑making.

Electrogastrography (EGG) and body surface gastric mapping (BSGM, e.g., Gastric Alimetry) are considered investigational: available studies report differences in spectral metrics and improved phenotyping versus older EGG methods, but evidence is insufficient that use of these tests results in improved patient‑important outcomes or should replace reference standards such as gastric emptying scintigraphy; additional validation and clinical utility studies are needed.

Esophageal mucosal integrity testing by electrical impedance (mucosal integrity or MI testing) is not established for use as a sole diagnostic screening tool. Published reviews conclude the evidence is limited, the device is not for use as a sole diagnostic screening tool, and additional clinical validity and clinical utility studies are needed before MI testing can replace standard testing such as pH monitoring, biopsies, or established diagnostic pathways.

Language pertaining to gastric electrical stimulation (GES) therapy was removed from this policy and has been relocated to the UnitedHealthcare Medical Policy titled Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Nebraska Only).

Consistent with the coverage rationale, the policy states that the listed procedures are considered unproven and not medically necessary because current evidence does not demonstrate sufficient effectiveness or impact on patient management. This includes MRI defecography, electrogastrography/electroenterography/BSGM, esophageal mucosal integrity testing, and FLIP for diagnosing achalasia.

For EGG/BSGM specifically, systematic reviews and evidence assessments reported heterogeneous methods, small study sizes, and very low‑quality evidence for some devices (for example, Gastric Alimetry), with no robust clinical utility studies demonstrating improved patient outcomes.

For MRI defecography, existing data suggest it is not consistently superior to conventional fluoroscopic defecography and therefore is not supported as a routine replacement in practice.

MRI defecography has mixed evidence and, according to systematic reviews and comparative studies, does not consistently replace conventional evacuation proctography; it may be inferior for detecting certain pelvic floor abnormalities in some series and is therefore considered an adjunctive or triage test rather than a routine substitute.

Electrogastrography and body surface gastric mapping currently lack sufficient evidence of diagnostic accuracy and clinical benefit to support routine clinical use; EGG/BSGM have not been shown to reliably improve management or outcomes compared with established tests.

Electrogastrography (EGG) remains experimental in many settings and guideline bodies such as the AGA have not recommended routine use of EGG for refractory gastroparesis or as a standard diagnostic modality. Comparative studies and meta-analyses report methodological heterogeneity and variable quality, and professional society guidance does not endorse EGG/BSGM as a substitute for established diagnostic tests.

The policy explicitly lists Functional Lumen Imaging Probe (FLIP) technology for diagnosing achalasia as unproven and not medically necessary. Although FLIP may provide complementary physiologic information, the policy adds FLIP for achalasia to the list of procedures considered not medically necessary for diagnostic use.

This revision removed previously listed device examples from the unproven/not medically necessary examples (including named systems such as Gastric Alimetry and the MiVu Mucosal Integrity Testing System) to streamline the list of technologies under evaluation; the policy retains the underlying coverage stance that cutaneous/mucous/serosal electrogastrography, body surface gastric mapping, and mucosal integrity testing remain unproven for routine diagnostic use.

Applicable and Removed Procedure/Regulatory Codes

Applicable procedure codes (reference list)CPT

0779T	Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report.
0868T	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report.
43499	Unlisted procedure, esophagus.
72195	Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s).
72196	Magnetic resonance (e.g., proton) imaging, pelvis; with contrast material(s).
72197	Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences.
76498	Unlisted magnetic resonance procedure (e.g., diagnostic, interventional).
91132	Electrogastrography, diagnostic, transcutaneous.
91133	Electrogastrography, diagnostic, transcutaneous; with provocative testing.

Referenced technologies (no explicit CPT/HCPCS codes listed in this excerpt)mixed

No codes listed

Regulatory product codes mentionedmixed

MYE / FFX	FDA product codes referenced for cutaneous EGG/BSGM and radiopaque markers
QIS	Product code referenced for MiVu Mucosal Integrity Testing System

Applicable Codes - removedCPT

43647	removed from Applicable Codes
43648	removed from Applicable Codes
43881	removed from Applicable Codes
43882	removed from Applicable Codes
64590	removed from Applicable Codes
64595	removed from Applicable Codes

inv-19: Test meal caloric content for BSGM protocol — 482 kilocalories

Test meal caloric content482 kilocalories

Source study (BSGM protocol)Gharibans et al. (2022) used a 482-kilocalorie meal in BSGM testing

ContextUsed as part of BSGM protocol including fasting baseline, meal ingestion, and postprandial recording

inv-20: BSGM postprandial recording duration — 4 hours

Postprandial recording duration4 hours

Protocol elements

Provider Responsibilities, Prior Authorization, and Documentation

Prior Authorization

Prior authorization and advanced testing

Prior authorization may be required per contract for certain advanced imaging and diagnostic procedures referenced in this policy. Verify prior authorization requirements with the member's plan before scheduling testing; authorization requirements vary by contract and may apply to MRI defecography, advanced gastric/enteric electrophysiology mapping, mucosal integrity testing, FLIP procedures, and other listed services.

Affected codes are listed in the Applicable Codes section and may require prior authorization per contract.
UnitedHealthcare may use third‑party utilization management tools (e.g., InterQual) to assist with authorization decisions.

Prior Authorization

Prior authorization recommended for advanced imaging/tests

Prior authorization is recommended for advanced imaging/tests when stepwise evaluation has not been completed or documentation is insufficient. Consider authorization for MRI defecography and other advanced tests only after initial, less‑invasive studies are performed and documented.

Preferred first‑line diagnostic tests include standardized reference studies (e.g., gastric emptying scintigraphy for gastroparesis, high‑resolution manometry for esophageal motility disorders).

Clinical Background

Constipation, fecal incontinence, and gastroparesis are common gastrointestinal conditions that frequently require physiologic testing to determine pathophysiology and guide management. Anorectal disorders and defecatory dysfunction are typically evaluated using basic anorectal testing (anorectal manometry and balloon expulsion test) and, when indicated, defecatory imaging; gastroparesis diagnosis requires objective demonstration of delayed gastric emptying with gastric emptying scintigraphy as the reference standard. Physiologic and specialized tests may aid diagnosis or surgical planning but should be considered in the context of established, evidence‑based diagnostic pathways.

Definitions

inv-38: Achalasia — definition of primary esophageal motor disorder

DefinitionA primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, impaired relaxation of the esophagogastric junction (EGJ), and loss of organized peristalsis in the esophageal body.

Clinical implicationLeads to impaired EGJ relaxation and absent or disordered peristalsis; relevant to diagnostic evaluation for achalasia

Source attributionDefinition per policy referencing ASGE wording

inv-39: Electrogastrography (EGG) — non-invasive measurement definition

DefinitionA non-invasive method for the measurement of gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

Method

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Disorders Diagnostic Procedures (for Nebraska Only)

Policy CodePolicy CS046NE.S

Change TypeTitle changerevisions to unproven procedure list and applicable codes

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionVerify member plan and obtain prior authorization when required before ordering advanced GI diagnostic procedures.

SourceLink

On This Page

ACG, AGA, and ASCRS guideline statements referenced.

Fasting baseline, ingestion of test meal, then four-hour postprandial recording for spectral and spatial biomarker analyses

Study contextGharibans et al. (2022) BSGM study employed a four-hour postprandial recording

Advanced imaging (MRI defecography) is generally reserved for cases where ARM and BET are inconclusive or discordant.

Document that conservative management and basic testing were attempted when applicable prior to advanced imaging.

Step Therapy

Stepwise evaluation and imaging after ARM/BET

Follow a stepwise diagnostic approach: begin with recommended first‑line tests and conservative management, then proceed to anorectal manometry (ARM) and balloon expulsion test (BET). Use defecatory imaging (fluoroscopic or MRI defecography) when ARM and BET results are inconclusive or discordant, or when structural causes of outlet obstruction are suspected.

ARM and BET generally suffice to diagnose or exclude a defecatory disorder; reserve defecography for equivocal cases.
Fluoroscopic defecography performed in the seated position is considered the evacuation examination with greatest construct validity; MRI defecography may be used for additional soft‑tissue detail.
Document the clinical rationale for proceeding to advanced imaging when ARM/BET are non‑diagnostic.

Denial Risk

Evidence insufficiency may trigger non‑coverage

Evidence for some procedures (for example, esophageal mucosal integrity testing and certain cutaneous/body surface gastric mapping techniques) is currently insufficient to establish clinical benefit. Lack of adequate evidence may result in these procedures being designated not medically necessary for coverage purposes and could lead to claim denials.

Examples of procedures with insufficient evidence are listed in the Coverage Rationale and may be denied as unproven/not medically necessary.
When novel device‑associated procedures are considered, document clinical indications and cite supporting evidence to assist medical review.

Note

Policy routing and relocated coverage

Policy routing and coverage responsibilities have changed: services or procedures moved or removed from this policy (for example, gastric electrical stimulation) are covered or evaluated under other named UnitedHealthcare policies. Check the Policy History and related Medical Policies to determine the current coverage location for a specific therapy or procedure.

GES and other procedures relocated from this policy may now be addressed under the Medical Policy titled 'Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Nebraska Only)'.
Review Policy History/Revision Information to confirm where a specific service is now governed.

Documentation Required

Documentation expectations for authorization and medical review

Document thoroughly in the medical record to support medical necessity and authorization requests. Include clinical indication, symptom history, prior conservative treatments, results of standard diagnostic testing (e.g., ARM, BET, gastric emptying scintigraphy, HRM), and the rationale for ordering advanced tests or device‑assisted diagnostics.

For imaging after ARM/BET, document ARM and BET findings and why imaging is needed (e.g., equivocal or discordant results).
When mucosal integrity testing or device measurements are performed during endoscopy, document endoscopic findings and MI/measurement values.
Retain records of standardized test protocols (e.g., scintigraphy meal consumption and imaging duration) when applicable.

Note

Check member plan and plan‑specific requirements

Verify member plan, federal/state, and contractual requirements before rendering services. Benefit coverage is governed by the applicable plan document and legal requirements; in the event of a conflict, those requirements control.

Check the member's specific plan for prior authorization, benefit limits, and any state‑specific mandates.
UnitedHealthcare reserves the right to modify policies; use the plan and current policy guidance when making coverage determinations.

Cutaneous electrodes record gastric myoelectrical signals (EGG) typically as low-resolution surface recordings

Intended useResearch and investigational assessment of gastric myoelectrical activity; clinical utility remains limited per policy

inv-40: Magnetic Resonance Defecography — definition of MRD

DefinitionA noninvasive MRI-based dynamic imaging test obtained at various stages of defecation to evaluate pelvic floor anatomy, dynamic motion, and rectal evacuation.

Clinical roleUsed to evaluate how well pelvic muscles work and to provide anatomic and functional detail for defecatory disorders

Comparison notePolicy describes MRD as an alternative imaging modality under study and generally adjunctive to conventional evacuation proctography

inv-41: Functional Lumen Imaging Probe (FLIP) — catheter-based endoscopic system definition

DefinitionA catheter-based endoscopic system designed to assess esophageal motility and to measure luminal diameter and pressure to evaluate esophageal distensibility and motility (example: EndoFLIP).

FunctionProvides continuous diameter measurements and applies pressure via an endolumenal balloon to assess compliance of the lower esophageal sphincter and esophagogastric junction dynamics

Role in practiceDescribed as a complementary tool; should not be used alone for diagnosis or treatment decisions

inv-42: Functional Lumen Imaging Probe (FLIP / EndoFLIP) — FDA-approved device definition

DefinitionAn FDA-cleared endolumenal device (EndoFLIP) that measures simultaneous luminal pressure and diameter to assess esophagogastric junction opening dynamics and esophageal wall stiffness during endoscopy.

Regulatory noteEndoFLIP has been available since 2009 and is described in the policy as an FDA-approved measurement tool used to guide management of upper GI disorders

Clinical guidanceAGA guidance states FLIP is complementary and clinicians should not make diagnoses or treatment decisions based on FLIP alone

inv-43: MRI defecography (MRD) — alternate definition entry

Definition (alternate)Dynamic MRI imaging performed during defecation to evaluate pelvic floor anatomy and defecatory function, used as an alternative to fluoroscopic evacuation proctography.

Use caseProvides simultaneous assessment of anatomy, motion, and rectal evacuation, and is useful when additional anatomic detail is needed for preoperative planning

Evidence notePolicy states MRD has mixed evidence and is generally adjunctive rather than a replacement for evacuation proctography

inv-44: Body Surface Gastric Mapping (BSGM) / Gastric Alimetry — definition for noninvasive multi-electrode mapping

DefinitionA noninvasive multi-electrode method to record gastric myoelectrical activity (spatial and spectral metrics) aiming to phenotype gastroduodenal disorders (example: Gastric Alimetry).

CapabilitiesRecords spatial and spectral biomarkers to improve phenotyping compared with traditional low-resolution EGG in some studies

Evidence cautionPolicy notes evidence is evolving and clinical utility to improve patient-important outcomes is not yet established

inv-45: BSGM — short key for Body Surface Gastric Mapping

Short formBSGM (Body Surface Gastric Mapping)

UsageUsed interchangeably with multi-electrode gastric mapping and Gastric Alimetry in the policy context

Evidence noteDescribed as investigational/adjunctive with evolving evidence

inv-46: EGG — short key for Electrogastrography

Short formEGG (Electrogastrography)

DescriptionNoninvasive cutaneous recording of gastric myoelectrical activity, typically low-resolution

Evidence notePolicy states EGG remains experimental/insufficiently supported for routine clinical diagnosis

inv-47: MI testing — Mucosal Integrity testing definition and example system

DefinitionIntraprocedural electrical impedance measurement of the esophageal epithelium performed during endoscopy to assess mucosal integrity (example system: MiVu balloon mucosal impedance catheter).

Intended purposeIntended to assist differentiation of GERD, EoE, and non-GERD by measuring impedance patterns along the esophagus during EGD

Regulatory exampleMiVu Mucosal Integrity Testing System received FDA de novo clearance in 2019 and subsequent 510(k) activity noted in policy FDA section

inv-48: Functional Lumen Imaging Probe (FLIP) — added definition in updated policy

Definition (updated)A catheter-based endoscopic system used to assess esophageal distensibility and motility by measuring lumen diameter and pressure (EndoFLIP exemplified); specifically added to policy definitions in the update.

Policy noteFLIP was added to policy definitions and listed among procedures evaluated for diagnosing achalasia in the April 1, 2026 revision

Clinical guidancePolicy describes FLIP as complementary and not to be used alone for diagnosis or treatment decisions

inv-49: Achalasia — added definition in updated policy

Definition (added)Achalasia: A primary esophageal motor disorder characterized by degeneration of the myenteric plexus leading to impaired EGJ relaxation and loss of organized peristalsis.

Policy changeDefinition for achalasia was explicitly added to the policy in the April 1, 2026 revision

Clinical relevanceAchalasia is specifically referenced in the policy in connection with FLIP technology for diagnosis, which the policy lists as unproven/not medically necessary